AXL positive	Non Small Cell Lung Cancer	AXL positive	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
AXL-L	Renal Cell Carcinoma	AXL-L	Renal Cell Carcinoma	cabozantinib tablet Sensitive: B - Late Trials cabozantinib tablet Sensitive : B	cabozantinib tablet Sensitive: B - Late Trials cabozantinib tablet Sensitive : B
AXL expression	Non Small Cell Lung Cancer	AXL expression	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2
AXL expression	Colorectal Cancer	AXL expression	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
AXL expression + EGFR mutation	Non Small Cell Lung Cancer	AXL expression + EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
AXL overexpression	Colorectal Cancer	AXL overexpression	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
AXL expression	Melanoma	AXL expression	Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
AXL expression	Renal Cell Carcinoma	AXL expression	Renal Cell Carcinoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
AXL elevation	Myelodysplastic Syndrome	AXL elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL elevation	Acute Myelogenous Leukemia	AXL elevation	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL-L	HER2 Positive Breast Cancer	AXL-L	HER2 Positive Breast Cancer	trastuzumab + TP-0903 Sensitive: C3 – Early Trials trastuzumab + TP-0903 Sensitive : C3	trastuzumab + TP-0903 Sensitive: C3 – Early Trials trastuzumab + TP-0903 Sensitive : C3
AXL expression	Non Small Cell Lung Cancer	AXL expression	Non Small Cell Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3

AXL (AXL Receptor Tyrosine Kinase)

Associations(39)

Associations
(39)